Biochemical Engineering
ReNeuron lays off 40% of staff after funding failure
19th January 2023
Iain Ross has made an immediate mark on ReNeuron, overseeing a restructuring to reduce the British biotech’s head count by 40% within weeks of taking the reins. The cuts extend the stem cell player’s cash runway out to 2024, partly easing the pressures that built up as it struggled to raise money last year. Source: Fierce Biotech 19/1/2023
Back to group news